1. Scrip

Santhera To Snap Up Second DMD Drug As Idorsia Climbs Aboard

 
• By Kevin Grogan

Actelion spin-off Idorsia is becoming the largest shareholder in Santhera after deciding its fellow Switzerland-based group is best placed to advance its optioned DMD candidate vamorolone.

Tennis
Santhera gets second shot at DMD • Source: Shutterstock

With one Duchenne muscular dystrophy (DMD) candidate already on its hands in Raxone (idebenone), Santhera is close to getting hold of another one - vamorolone - through a option deal inked with fellow Swiss group Idorsia.

Santhera has bought the rights to sub-license vamorolone, which was discovered and is being developed by Reveragen BioPharma Inc. of the US. Actelion Pharmaceuticals Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.